Navigation Links
Inscent, Inc. Receives Federal Grant to Develop Honeybee Repellents

IRVINE, Calif., April 28 /PRNewswire/ -- Inscent, Inc. has received a Small Business Innovative Research grant from the US National Science Foundation (NSF) to continue the testing and development of novel honeybee repellents using the proprietary Attenu high throughput assay system. The pioneering research performed by Inscent, Inc. has resulted in highly efficient processes that allow the rapid development of revolutionary insect control products suited for the modern age. Inscent's groundbreaking paradigm shift away from traditional insecticides and toward products based on behavior alteration of targeted species has been supported extensively by federal research grants and private industry funds. NSF reviewers described the honeybee repellent project as "fascinating" and "highly desirable," and new federal funding commences in July 2008.

Inscent, Inc. is designing environmentally responsible insect control products that will eclipse the current generation of insecticides. The company's latest efforts focus on the honeybee, Apis mellifera, an economically and agriculturally crucial insect species, for the development of a new array of insect control products based on behavior alteration. Inscent's honeybee repellent project was originally funded by the Citrus Research Board (CRB;, a coalition of California growers at the global forefront of citrus industry-funded scientific research.

The honeybee, Apis mellifera, is critical to US agriculture, and a Cornell University study estimated the direct value of honeybee pollination in this country exceeds $14 billion annually. Although the initial use of the repellent will be to prevent seediness in mandarins, it will also provide a solution for keeping bees out of fields that have been treated with insecticides. Honeybees are threatened by insecticide use and recent incidents of colony collapse have caused great concern among the farming and apiculture industries. These factors have combined to generate an urgent need for effective products that are safe to humans and insects alike.

Inscent, Inc. has developed a number of novel platform technologies to exploit the wide variety, selectivity, and high sensitivity of insect chemosensory systems. This proprietary collection of chemosensory proteins is being used to develop a series of non-toxic, highly efficient insect pest control products. Inscent's new technologies are applicable to a wide array of insect pest species that impact the agricultural, domestic, and public health sectors. Inscent's platform technologies utilize the latest developments in molecular genetics, genomics, and bioinformatics to design advanced, environmentally responsible insect pest control solutions and effective, sensitive biosensors. Further information on Inscent is available on the web at

The National Science Foundation is an independent federal agency that supports fundamental research and education across all fields of science and engineering. NSF also encourages scientific innovation and discovery in the commercial sector, primarily through the Small Business Innovative Research (SBIR) program. Further information on NSF is available on the web at

Inscent, Inc. welcomes inquiries from qualified investors and potential strategic allies.

SOURCE Inscent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family ... tests directly from their electronic medical record (EMR) without the need for redundant ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... all, Water For Empowerment ™ attracts volunteers together who want to combine ... empowering women as key stakeholders in the process. The non-profit launched its first ...
(Date:11/25/2015)... NV (PRWEB) , ... November 25, 2015 , ... Dr. ... patients to learn more about hair loss treatment with the Capillus272™ Pro laser therapy ... effective solution for thicker and fuller hair, without the need for surgery, prescription pills, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology: